UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
DERMATOLOGY & AESTHETICS

Cutera

Aesthetic medical devices for skin and body treatments

Cutera logo

Cutera

Dermatology & AestheticsBrisbane, United States

Aesthetic medical devices for skin and body treatments

Visit Website

About Cutera

Cutera has built its reputation on energy-based aesthetic medicine, developing and commercialising laser, light, and radiofrequency systems used by dermatologists, plastic surgeons, and aesthetic practitioners worldwide. Founded in 1998 and headquartered in Brisbane, California, the company is publicly listed on Nasdaq under the ticker CUTR.

The company's portfolio spans a range of energy-based aesthetic devices, covering applications in body contouring, skin resurfacing, vascular treatment, hair removal, and acne management. Its systems include the truSculpt platform for non-invasive body shaping, the excel V+ laser for vascular and pigmented lesions, and the Secret PRO device combining fractional radiofrequency with laser resurfacing. These platforms are sold and supported across North America, Europe, Asia-Pacific, and other international markets.

Cutera's commercial model centres on capital equipment sales to aesthetic practices alongside recurring revenue from consumables and service agreements. The company serves a broad clinical base, from solo aesthetic practices to large multi-site groups, positioning its devices as practice-building platforms rather than single-indication tools. Training and clinical education support are provided to practitioners adopting its systems.

Further information is available at cutera.com.

Areas of Expertise

Aesthetic MedicineBody ContouringDermatologyHair RemovalSkin Resurfacing

Services & Capabilities

Aesthetic MedicineBody ContouringDermatologyHair RemovalSkin Resurfacing
Similar Companies

More in Dermatology & Aesthetics

M

Merz Aesthetics

Merz Aesthetics is the dedicated aesthetics division of Merz Pharmaceuticals, a family-owned German healthcare company with roots stretching back to 1908. Where many aesthetics companies are relatively young, Merz brings more than a century of pharmaceutical heritage to a sector it has helped define.The division focuses exclusively on medical aesthetics, offering a portfolio spanning neurotoxins, dermal fillers, and energy-based device technologies. Its neurotoxin brand Xeomin (incobotulinumtoxinA) is approved in multiple markets for both aesthetic and therapeutic indications, and is notable for its purified formulation, which contains no complexing proteins. The Belotero range of hyaluronic acid fillers addresses a broad spectrum of facial rejuvenation needs, from fine lines to volumisation.Merz Aesthetics operates globally, with a significant commercial presence across North America, Europe, and Asia-Pacific. The division is headquartered in Raleigh, North Carolina, reflecting the strategic importance of the United States as its largest aesthetics market, while its parent company remains based in Frankfurt, Germany.Beyond injectables, the company has expanded into energy-based devices through partnerships and acquisitions, broadening its offering to aesthetic practitioners who seek a more comprehensive treatment portfolio. Its education and training programmes for healthcare professionals are a recognised part of its commercial model, supporting clinical best practice alongside product adoption.As a privately held entity within the Merz family group, the division is not publicly listed, allowing a longer-term investment horizon than many listed peers. This structure has supported sustained investment in clinical evidence and product development across its core categories.Further information is available at merzaesthetics.com.

View profile
A

Alcyomics

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

View profile
4

4MCS

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research. The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy